Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy

George Somlo, Paul Frankel, Warren Chow, Lucille Leong, Kim Margolin, Robert Morgan, Stephen Shibata, Peiguo Chu, Stephen Forman, Dean Lim, Przemyslaw Twardowski, Jeffrey Weitzel, Joseph Alvarnas, Neil Kogut, Jeffrey Schriber, Eleanor Fermin, Yun Yen, Lloyd Damon, James H. Doroshow

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Purpose: To improve treatment outcome for patients presenting with inflammatory breast cancer (IBC), we have sequentially developed and tested single and tandem dose-intense chemotherapy regimens (DICT). Tumor- and treatment-related factors were analyzed to generate a prognostic model. Patients and Methods: Between May 1989 and April 2002, 120 patients received conventional-dose chemotherapy, surgery, and sequentially developed single- or tandem-cycle DICT. Disease- and treatment-specific features were subjected to univariate and multivariate analysis to correlate with outcome. Results: At a median follow-up of 61 months (range, 21 to 161 months), estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 44% (95% CI, 34% to 53%) and 64% (95% CI, 55% to 73%), respectively. In an age-adjusted multivariate analysis, RFS was better in patients with estrogen receptor (ER)/progesterone receptor (PR)-positive tumors (P = .002), for patients with fewer than four involved axillary nodes before DICT (P = .01), and in patients treated with radiation therapy (P = .001) and tandem DICT (P = .049). OS was improved in patients with ER/PR-positive tumors (P = .002), in those with fewer than four involved axillary nodes before DICT (P = .03), and in patients treated with radiation therapy (P = .002). Conclusion: This retrospective analysis suggests that either single or tandem DICT can be administered safely and may benefit selected patients with stage IIIB IBC. Those with receptor-negative IBC and with four or more involved axillary nodes before DICT need improved neoadjuvant and postadjuvant intensification therapy. A prospective randomized trial of single versus tandem DICT would be required to confirm the potential benefit of tandem DICT in the setting of IBC.

Original languageEnglish
Pages (from-to)1839-1848
Number of pages10
JournalJournal of Clinical Oncology
Volume22
Issue number10
DOIs
Publication statusPublished - Dec 1 2004
Externally publishedYes

Fingerprint

Inflammatory Breast Neoplasms
Drug Therapy
Survival
Progesterone Receptors
Estrogen Receptors
Radiotherapy
Multivariate Analysis
Recurrence
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. / Somlo, George; Frankel, Paul; Chow, Warren; Leong, Lucille; Margolin, Kim; Morgan, Robert; Shibata, Stephen; Chu, Peiguo; Forman, Stephen; Lim, Dean; Twardowski, Przemyslaw; Weitzel, Jeffrey; Alvarnas, Joseph; Kogut, Neil; Schriber, Jeffrey; Fermin, Eleanor; Yen, Yun; Damon, Lloyd; Doroshow, James H.

In: Journal of Clinical Oncology, Vol. 22, No. 10, 01.12.2004, p. 1839-1848.

Research output: Contribution to journalArticle

Somlo, G, Frankel, P, Chow, W, Leong, L, Margolin, K, Morgan, R, Shibata, S, Chu, P, Forman, S, Lim, D, Twardowski, P, Weitzel, J, Alvarnas, J, Kogut, N, Schriber, J, Fermin, E, Yen, Y, Damon, L & Doroshow, JH 2004, 'Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy', Journal of Clinical Oncology, vol. 22, no. 10, pp. 1839-1848. https://doi.org/10.1200/JCO.2004.10.147
Somlo, George ; Frankel, Paul ; Chow, Warren ; Leong, Lucille ; Margolin, Kim ; Morgan, Robert ; Shibata, Stephen ; Chu, Peiguo ; Forman, Stephen ; Lim, Dean ; Twardowski, Przemyslaw ; Weitzel, Jeffrey ; Alvarnas, Joseph ; Kogut, Neil ; Schriber, Jeffrey ; Fermin, Eleanor ; Yen, Yun ; Damon, Lloyd ; Doroshow, James H. / Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 10. pp. 1839-1848.
@article{22d1647713fa4936926e570528eda09f,
title = "Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy",
abstract = "Purpose: To improve treatment outcome for patients presenting with inflammatory breast cancer (IBC), we have sequentially developed and tested single and tandem dose-intense chemotherapy regimens (DICT). Tumor- and treatment-related factors were analyzed to generate a prognostic model. Patients and Methods: Between May 1989 and April 2002, 120 patients received conventional-dose chemotherapy, surgery, and sequentially developed single- or tandem-cycle DICT. Disease- and treatment-specific features were subjected to univariate and multivariate analysis to correlate with outcome. Results: At a median follow-up of 61 months (range, 21 to 161 months), estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 44{\%} (95{\%} CI, 34{\%} to 53{\%}) and 64{\%} (95{\%} CI, 55{\%} to 73{\%}), respectively. In an age-adjusted multivariate analysis, RFS was better in patients with estrogen receptor (ER)/progesterone receptor (PR)-positive tumors (P = .002), for patients with fewer than four involved axillary nodes before DICT (P = .01), and in patients treated with radiation therapy (P = .001) and tandem DICT (P = .049). OS was improved in patients with ER/PR-positive tumors (P = .002), in those with fewer than four involved axillary nodes before DICT (P = .03), and in patients treated with radiation therapy (P = .002). Conclusion: This retrospective analysis suggests that either single or tandem DICT can be administered safely and may benefit selected patients with stage IIIB IBC. Those with receptor-negative IBC and with four or more involved axillary nodes before DICT need improved neoadjuvant and postadjuvant intensification therapy. A prospective randomized trial of single versus tandem DICT would be required to confirm the potential benefit of tandem DICT in the setting of IBC.",
author = "George Somlo and Paul Frankel and Warren Chow and Lucille Leong and Kim Margolin and Robert Morgan and Stephen Shibata and Peiguo Chu and Stephen Forman and Dean Lim and Przemyslaw Twardowski and Jeffrey Weitzel and Joseph Alvarnas and Neil Kogut and Jeffrey Schriber and Eleanor Fermin and Yun Yen and Lloyd Damon and Doroshow, {James H.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1200/JCO.2004.10.147",
language = "English",
volume = "22",
pages = "1839--1848",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy

AU - Somlo, George

AU - Frankel, Paul

AU - Chow, Warren

AU - Leong, Lucille

AU - Margolin, Kim

AU - Morgan, Robert

AU - Shibata, Stephen

AU - Chu, Peiguo

AU - Forman, Stephen

AU - Lim, Dean

AU - Twardowski, Przemyslaw

AU - Weitzel, Jeffrey

AU - Alvarnas, Joseph

AU - Kogut, Neil

AU - Schriber, Jeffrey

AU - Fermin, Eleanor

AU - Yen, Yun

AU - Damon, Lloyd

AU - Doroshow, James H.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Purpose: To improve treatment outcome for patients presenting with inflammatory breast cancer (IBC), we have sequentially developed and tested single and tandem dose-intense chemotherapy regimens (DICT). Tumor- and treatment-related factors were analyzed to generate a prognostic model. Patients and Methods: Between May 1989 and April 2002, 120 patients received conventional-dose chemotherapy, surgery, and sequentially developed single- or tandem-cycle DICT. Disease- and treatment-specific features were subjected to univariate and multivariate analysis to correlate with outcome. Results: At a median follow-up of 61 months (range, 21 to 161 months), estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 44% (95% CI, 34% to 53%) and 64% (95% CI, 55% to 73%), respectively. In an age-adjusted multivariate analysis, RFS was better in patients with estrogen receptor (ER)/progesterone receptor (PR)-positive tumors (P = .002), for patients with fewer than four involved axillary nodes before DICT (P = .01), and in patients treated with radiation therapy (P = .001) and tandem DICT (P = .049). OS was improved in patients with ER/PR-positive tumors (P = .002), in those with fewer than four involved axillary nodes before DICT (P = .03), and in patients treated with radiation therapy (P = .002). Conclusion: This retrospective analysis suggests that either single or tandem DICT can be administered safely and may benefit selected patients with stage IIIB IBC. Those with receptor-negative IBC and with four or more involved axillary nodes before DICT need improved neoadjuvant and postadjuvant intensification therapy. A prospective randomized trial of single versus tandem DICT would be required to confirm the potential benefit of tandem DICT in the setting of IBC.

AB - Purpose: To improve treatment outcome for patients presenting with inflammatory breast cancer (IBC), we have sequentially developed and tested single and tandem dose-intense chemotherapy regimens (DICT). Tumor- and treatment-related factors were analyzed to generate a prognostic model. Patients and Methods: Between May 1989 and April 2002, 120 patients received conventional-dose chemotherapy, surgery, and sequentially developed single- or tandem-cycle DICT. Disease- and treatment-specific features were subjected to univariate and multivariate analysis to correlate with outcome. Results: At a median follow-up of 61 months (range, 21 to 161 months), estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 44% (95% CI, 34% to 53%) and 64% (95% CI, 55% to 73%), respectively. In an age-adjusted multivariate analysis, RFS was better in patients with estrogen receptor (ER)/progesterone receptor (PR)-positive tumors (P = .002), for patients with fewer than four involved axillary nodes before DICT (P = .01), and in patients treated with radiation therapy (P = .001) and tandem DICT (P = .049). OS was improved in patients with ER/PR-positive tumors (P = .002), in those with fewer than four involved axillary nodes before DICT (P = .03), and in patients treated with radiation therapy (P = .002). Conclusion: This retrospective analysis suggests that either single or tandem DICT can be administered safely and may benefit selected patients with stage IIIB IBC. Those with receptor-negative IBC and with four or more involved axillary nodes before DICT need improved neoadjuvant and postadjuvant intensification therapy. A prospective randomized trial of single versus tandem DICT would be required to confirm the potential benefit of tandem DICT in the setting of IBC.

UR - http://www.scopus.com/inward/record.url?scp=3042697186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042697186&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.10.147

DO - 10.1200/JCO.2004.10.147

M3 - Article

VL - 22

SP - 1839

EP - 1848

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -